Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
Functional expressions of EGFP/LKB1 and its kinase domain induced apoptosis and enhanced chemosensitivity in lung cancer cell lines Source: Eur Respir J 2004; 24: Suppl. 48, 5s Year: 2004
Characteristics and prognostic relevance of p 53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005
Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002
Detection of epidermal growth factor receptor mutation in plasma as predictor of gefitinib response in non small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
The effect of siRNA on invasion capability of small cell lung cancer Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012
Telomerase activity as a prognostic marker in non small cell lung cancer Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology Year: 2008
A low endothelial cell proliferation fraction, a measurement of ongoing angiogenesis, is associated with poor prognosis in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 763s Year: 2006
Association between protein expression of p63 and final cause of death in non small cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
GSK-3 inhibition suppresses lung cancer cell survival, metastasis and proliferation through down-regulation the phosphorylation sites of CAP1 Source: International Congress 2017 – Lung cancer - basic science: the latest results from the bench Year: 2017
Nuclear expression of Y-Box binding protein (YB-1) as a negative prognostic marker in non-small cell lung cancer Source: Annual Congress 2003 - Lung cancer biology Year: 2003
The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003
NEUROD1 is highly expressed in extensive disease small cell lung cancer by promoting migration. Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020
Akt induced cytoplasmic mislocalization of p27kip1 protein and correlated with poor prognosis in lung adenocarcinoma Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours Year: 2008
Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer Source: Eur Respir J 2004; 23: 14-19 Year: 2004
Inhibition of insulin-like growth factor type I (IGF-I) gene in A549 human lung cancer cell line enhances cell apoptosis and causes phenotype changes relevant to increased tumor susceptibility to immune system Source: Eur Respir J 2007; 30: Suppl. 51, 715s Year: 2007
The expression of central cell cycle regulators in non-small cell lung cancer has therapy-dependent prognostic impact Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012